

Company update

Dr Jim Millen (NED Chairman) and Dr Peter Sargent (CEO)

29 January 2024

Disclaimer

The information contained in this presentation ("Presentation") has been prepared by Physiomics Plc (the "Company"). This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 ("FSMA"). This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as maybe deemed necessary. Any person who receives this Presentation should not rely or act upon it. Any person who is in any doubt about this Presentation should consult a person duly authorised for the purposes of FSMA who specialises in the acquisition of shares and other securities.

Whilst the information contained in this Presentation has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation. All statements of opinion and/or belief contained in this Presentation and all views expressed represent the directors' own current assessment and interpretation of information available to them as at the date of this Presentation.

This Presentation has not been fully or independently verified and is subject to material updating, revision and further amendment. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.

This Presentation contains certain forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements include, but are not limited to, statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, growth, forecasts, projections, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Therefore, actual results and future events could differ materially from those anticipated in such statements. Risks and uncertainties that could cause results of future events to differ materially from current expectations expressed or implied by the forward-looking statements include, but are not limited to, loss of major customer(s), competition and pricing pressure, personnel and skills, requirements of additional financing risk, regulation changes, systems and infrastructure, the COVID-19 pandemic, and other risks. No representation is made or assurance given that such statements or views are correct or that the objectives of the Company will be achieved. The reader is cautioned not to place reliance on these statements or views and no responsibility is accepted by the Company or any of its shareholders, directors, officers, agents, employees or advisers in respect thereof.

This Presentation should not be considered as the giving of investment advice by the Company, or any of its shareholders, directors, officers, agents, employees or advisers in relation to the acquisition of shares in the Company. In particular, this Presentation does not constitute an offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever.

Neither this Presentation nor any copy of it may be: (a) taken or transmitted into Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa or the United States of America (each a "Restricted Territory"), their territories or possessions; (b) distributed to any US person (as defined in Regulation S under the United States Securities Act of 1933 (as amended)); or (c) distributed to any individual outside a Restricted Territory who is a resident thereof, in any such case for the purpose of offer for sale or solicitation or invitation to buy or subscribe any securities or in the context where its distribution may be construed as such offer, solicitation or invitation, in any such case except in compliance with any applicable exemption. The distribution of this document in or to persons subject to other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction.

By accepting receipt or attending any delivery of, or electronically accessing, this Presentation, each recipient agrees to be bound by the above limitations and conditions and, in particular represents, warrants and undertakes to the Company that: (i) they will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose; and (ii) they agree to comply with the contents of this notice.



Dr Peter Sargent
CEO



Dr Jim Millen
NED Chairman

Agenda

1. Introducing the new CEO and the transition
2. Immediate Areas of Focus
3. Q&A



New CEO: Introducing Dr Peter Sargent



PhD (MRC Industrial Collaborative)
Biochemistry and Biophysics, King's College London

Innovation Scout, British Biocell International
Search and Evaluation role developing **partnerships with industry and academia**

Head of Business Development for National Institute for Health Research
Worked with UK Government around advising life science businesses **grow within the UK**

BSc & MSc
Microbiology, University of Liverpool / School of Tropical Medicine

Head of R&D Diagnostics Business
Development of award-winning new products, **growing revenues** by (4-5x), **positioning for sale**

Director, hVIVO plc
Led R&D and commercial teams in a **high growth** AIM listed business, developing **new service arms towards Pharma**

Strategy Consulting at Syneos Health
Global **consultancy** practice support emerging to top-tier biopharma with **R&D transformation**

Physiomics plc

Sept 2023:
Joined as COO



Jan 2024:
Transitioned to CEO



Immediate Areas of Focus

Growth and Profit

1.
 - ✓ Driving the pipeline
 - ✓ Increasing conversion
 - ✓ Diversifying client base
 - ✓ Broaden our offer
 - ✓ Building new capabilities
 - ✓ Operational Excellence
2.
 - ✓ Accelerate service roll-out
 - ✓ Offer development
 - ✓ Capability build (de novo vs acquisition)
3.
 - ✓ Retain focus on Innovate funding trial
 - ✓ Refresh plans
 - ✓ Build on existing partnerships

Consulting Services


Products

Data Science and
Mathematical
Modelling
(Core)

Biometrics (Biostats)
(New)

Personalised Medicine

Foundations



Contacts:

- Physiomics plc, info@physiomics.co.uk
- Hybridan LLP, Broker, research@hybridan.com